|
|
Truvada (Tenofovir/FTC)
| Brand Name: |
Truvada |
| Generic Name: |
Emtricitabine + tenofovir disoproxil
fumarate, FTC/TDF |
| Adult Single Dose: |
One tablet containing 200 mg FTC
and 300 mg TDF (once a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NRTI |
|
|
|
The Basics
- An Overview of Truvada (Tenofovir/FTC) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- FAQs About Truvada (Regularly Updated)
From The Body's "Ask the Experts" Forums
- Truvada (Tenofovir/Emtricitabine, TDF/FTC) (January/February 2008)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Truvada (Viread + Emtriva) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Patient Information About Truvada (Tenofovir/FTC) (PDF) (May 2007)
From Gilead Sciences, Inc.
- Truvada (Tenofovir + Emtricitabine) (April 22, 2006)
To read PDF, click here
From AIDS InfoNet
- Patient Assistance Programs (January 2005)
Having problems paying for Truvada? Visit Gilead's patient assistance program page.
From Gilead Sciences, Inc.
- Understanding Two New Once-a-Day Combinations: Truvada and Epzicom (November/December 2004)
Daniel S. Berger, M.D., reviews issues of drug concentrations, adherence and resistance.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- New Fixed-Dose Once-a-Day Starting Regimens: Interview With Cal Cohen, M.D. (October 26, 2004)
A leading AIDS physician looks at the advantages and disadvantages of Epzicom and Truvada for those who are first starting antiretroviral treatment.
In AIDS Treatment News, from AIDS Treatment News
News
- Gilead Lowers Its No-Profit Drug Prices for Truvada, Viread (August 30, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Gilead's Fixed-Dose Combination of Truvada + Efavirenz Not Yet Bioequivalent to Drugs Alone (August 10, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- FDA Approves Two Combination Pills, Epzicom and Truvada; Comment on Commercial Race to Once-a-Day Nucleosides (August 23, 2004)
The benefits of once-a-day drugs haven't been adequately weighed against their potential risks, writes AIDS advocate John James.
In AIDS Treatment News, from AIDS Treatment News
- FDA Approves Gilead, GlaxoSmithKline Fixed-Dose Combination AIDS Drugs (August 3, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration
Research
- Switching From Zidovudine/Lamivudine to Tenofovir/Emtricitabine: Results of an Uncontrolled Cohort (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
- HIV JournalView: Tenofovir + Emtricitabine + Efavirenz vs. Zidovudine/Lamivudine + Efavirenz (February/March 2006)
An important study by Joel Gallant et al demonstrates the advantage of tenofovir + FTC in first-line therapy.
From The Body PRO
- Data Supports Bioequivalence for Once-Daily, Single-Pill, Fixed-Dose Combination of Sustiva and Truvada, Drug Companies Announce (January 9, 2006)
Filing of a new drug application is expected in the second quarter of 2006.
To read PDF, click here
From Bristol-Myers Squibb Company and Gilead Sciences, Inc.
- In Head-to-Head International Study, Tenofovir + Emtricitabine Bests Zidovudine/Lamivudine in Tolerability and Convenience (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- No K65R Mutations in Patients Failing Tenofovir + Emtricitabine (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Truvánadu: Does Gilead's Famed 903 Study Really Show You What They Tell You It Shows? (December 2004)
A highly critical examination of the manner in which many clinical trials are designed.
In TAGline, from Treatment Action Group
- Little Leap: Gilead 2-in-1 Opens Door to Impending One-Pill Triple Combo (October 2004)
Rob Camp reports on the generally underwhelming news of the launch of Truvada and Epzicom.
In TAGline, from Treatment Action Group
|
|
